认知未受损及轻度受损老年人的就诊间血压变异性与脑脊液阿尔茨海默病生物标志物
该研究基于阿尔茨海默病神经影像学倡议的前瞻性队列进行回顾性分析,纳入466名认知未受损或轻度受损的老年人,在12个月内进行3至4次血压测量,并在随访时(6至108个月后)接受腰椎穿刺检测脑脊液磷酸化tau、总tau和β-淀粉样蛋白水平。结果显示,就诊间血压变异性升高与随访时脑脊液磷酸化tau升高、总tau升高和β-淀粉样蛋白降低相关;APOE ε4携带者中血压变异性升高与磷酸化tau升高最快相关。
要点
- 血压变异性升高与随访时脑脊液磷酸化tau升高、总tau升高及β-淀粉样蛋白降低相关。
- APOE ε4携带者中,血压变异性升高与磷酸化tau水平升高最快相关。
- 血压变异性与总tau或β-淀粉样蛋白水平随时间的关系未因APOE ε4携带状态而显著不同。
核心结论
- 老年人血压变异性升高与随访时脑脊液磷酸化tau升高、总tau升高和β-淀粉样蛋白降低相关,提示血压变异性可能与阿尔茨海默病生物标志物改变相关。
- 研究结果提示需进一步研究血压变异性与阿尔茨海默病发生之间的关系。
- APOE ε4携带状态调节血压变异性与脑脊液磷酸化tau的关系,但不调节与总tau或β-淀粉样蛋白的关系。
研究设计与样本
- 本研究为前瞻性队列研究的回顾性分析,纳入来自阿尔茨海默病神经影像学倡议的认知未受损或轻度受损老年人。
- 参与者在12个月内接受3至4次血压测量,并在随访时(6至108个月后)接受至少1次腰椎穿刺以评估脑脊液磷酸化tau、总tau和β-淀粉样蛋白水平。
- APOE ε4携带者定义为具有至少1个ε4等位基因。
- 就诊间血压变异性通过12个月内的独立于均值的变异性确定。
- 采用贝叶斯线性增长模型分析血压变异性、APOE ε4和时间推移对脑脊液生物标志物水平的作用,并控制包括平均血压和基线高血压在内的多个变量。
主要发现
- 共纳入466名参与者,平均年龄76.7岁(标准差7.1)。
- 血压变异性升高与随访时脑脊液磷酸化tau升高相关(β = 0.81 [95% CI 0.74, 0.97])。
- 血压变异性升高与随访时脑脊液总tau升高相关(β = 0.98 [95% CI 0.71, 1.31])。
- 血压变异性升高与随访时脑脊液β-淀粉样蛋白降低相关(β = -1.52 [95% CI -3.55, -0.34])。
- APOE ε4携带者中血压变异性升高与磷酸化tau水平升高最快相关(β = 9.03 [95% CI 1.67, 16.36])。
关键数值与推荐
- 血压变异性升高与随访时脑脊液磷酸化tau升高相关(β = 0.81 [95% CI 0.74, 0.97])。
- 血压变异性升高与随访时脑脊液总tau升高相关(β = 0.98 [95% CI 0.71, 1.31])。
- 血压变异性升高与随访时脑脊液β-淀粉样蛋白降低相关(β = -1.52 [95% CI -3.55, -0.34])。
- APOE ε4携带者中血压变异性升高与磷酸化tau水平升高最快相关(β = 9.03 [95% CI 1.67, 16.36])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Blood pressure variability is an emerging risk factor for cognitive decline and dementia, but mechanisms remain unclear. The current study examined whether visit-to-visit blood pressure variability is related to CSF Alzheimer disease biomarker levels over time and whether associations differed by APOE ε4 carrier status. METHODS: In this retrospective analysis of a prospective cohort study, cognitively unimpaired or mildly impaired older adults from the Alzheimer's Disease Neuroimaging Initiative underwent 3 to 4 blood pressure measurements over a 12-month period and ≥1 lumbar puncture for evaluation of CSF phosphorylated tau, total tau, and β-amyloid levels at follow-up (6-108 months later). APOE ε4 carriers were defined as having ≥1 ε4 allele. Visit-to-visit blood pressure variability was determined over 12 months as variability independent of mean. Only CSF samples collected after the final blood pressure measurement were analyzed. Bayesian linear growth modeling investigated the role of blood pressure variability, APOE ε4, and the passage of time on CSF biomarker levels after controlling for several variables, including average blood pressure and baseline hypertension. RESULTS: Four hundred sixty-six participants (mean 76.7 [SD 7.1] years of age) were included in the study. Elevated blood pressure variability was associated with increased CSF phosphorylated tau (β = 0.81 [95% CI 0.74, 0.97]), increased total tau (β = 0.98 [95% CI 0.71, 1.31]), and decreased β-amyloid levels (β = -1.52 [95% CI -3.55, -0.34]) at follow-up. APOE ε4 carriers with elevated blood pressure variability had the fastest increase in phosphorylated tau levels (β = 9.03 [95% CI 1.67, 16.36]). Blood pressure variability was not significantly related to total tau or β-amyloid levels over time according to APOE ε4 carrier status. DISCUSSION: Older adults with elevated blood pressure variability exhibit increased CSF phosphorylated tau, increased total tau, and decreased β-amyloid over time, suggesting that blood pressure variability may correlate with alterations in Alzheimer disease biomarkers. Findings warrant further study of the relationship between blood pressure variability and the development of Alzheimer disease. APOE ε4 carrier status moderated relationships between blood pressure variability and CSF phosphorylated tau but not total tau or β-amyloid, consistent with other studies relating hemodynamic factors to tau changes.
引用
- Sible IJ, Nation DA. Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults. Neurology. 2022. PMID: 35418462. doi:10.1212/WNL.0000000000200302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。